Source | M.W. | 272.3 | CAS No. | 396129-53-6 | |
---|---|---|---|---|---|
Structural Info | [3-(Pyridin-2-yl)-4-(4-quinonyl)]-1H-pyrazole | ||||
Formulation | Powder | ||||
Reconstitution | Before reconstitution, we recommend a brief spin todrive down any material dislodged from the bottom of the tube. The compound is soluble in DMSO. | ||||
Stability | The powder is stable for at least 2 year if stored at-20 °C. The dissolved compound isstable for at least 1 month at 4 °C, but should be stored in aliquots at-20 °C for longer term. Protectfrom light. | ||||
Purity | Greater than 98% as determined by LC/MS analysis.LC/MS and/or NMR data available upon request. | ||||
Biological Activity | In a cell-based assay measuring the activation of a SMAD reporter gene, this compound gives IC50 around 100-200 nM. | ||||
Country of Origin | USA |
Selective inhibitor of TGF-β type-I receptor (IC50 59 nM for TGF-β RI vs. 400 nM for TGF-βRII). [3-(Pyridin-2-yl)-4-(4-quinonyl)]-1H-pyrazoleRef: Sawyeret al. Synthesisand activity of new aryl- and heteroaryl-substituted pyrazole inhibitors of thetransforming growth factor-μ type I receptor kinase domain. J. Med. Chem. 46 3953, 2003.